Drug · Small Molecule

Selinexor

CI-DRUG-00000545Explore in graph →NCIt C102546 CHEMBL3545185 CIViC Approved

Regulatory

Approvals (7)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory7 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as XPOVIO (DIN 02527677) under ATC L01XX66 SELINEXOR. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 7, 2022	health-canada-dpd
EU EMA	Multiple Myeloma	NEXPOVIO is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	approved	Mar 26, 2021	ema
US FDA	—	Efficacy supplement 2026-04-23 (see label)	approved	Apr 23, 2026	openfda

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 14 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	60	30	16	148	7	CA, EU, US	Jul 3, 2019	Jun 18, 2012
Non-Hodgkin Lymphoma	Approved	Phase 4	25	12	6	53	3	EU, US	Jul 3, 2019	Jun 12, 2014
Multiple Myeloma	Approved	Phase 3	21	11	6	39	3	EU, US	Jul 3, 2019	Jun 12, 2014
Leukemia	Phase3	Phase 3	9	2	1	25	0	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 ITD & Y842C1
Selinexor + Sorafenib

Clinical trials

Trials with this intervention (153)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 153 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05432804	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	recruiting	Phase 1 / Phase 2	97	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT05099003	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Molecule

Record

Kind: Small Molecule
Mechanism: Exportin-1 inhibitor
Targets: 1 gene
UNII: 31TZ62FO8F
Aliases: 2-Propenoic Acid, 3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-Pyrazinyl)hydrazide, (2Z)-, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT 330, KPT-330, KPT330, Nexpovio, Selective Inhibitor Of Nuclear Export KPT-330, Selinexor, SINE KPT-330, Xpovio, XPOVIO

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (4)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XX66	SELINEXOR
DIN (Health Canada)	02527677	XPOVIO
DPD drug code